BREPCO BIOPHARMA LIMITED

BrePco Biopharma Limited is a specialised pharmaceutical company that holds the marketing authorisation for Neoatricon® (dopamine hydrochloride), a ready‑to‑use, infant‑suitable formulation of dopamine. The product is uniquely approved across the European Union for the treatment of hypotension in haemodynamically unstable neonates, infants and children up to 18 years of age, making it the sole dopamine preparation authorised for paediatric use in the EU.

The company’s core focus is on delivering this life‑saving therapy to hospitals and neonatal intensive‑care units, ensuring that vulnerable patients receive a safe, precisely dosed medication that meets the stringent requirements of paediatric care. By concentrating on this niche yet critical therapeutic area, BrePco Biopharma supports clinicians in stabilising young patients whose cardiovascular systems are compromised.

Headquartered in Dublin’s Sandyford Business Park, BrePco Biopharma combines scientific rigour with a patient‑centred approach, positioning itself as a trusted partner for healthcare professionals seeking reliable solutions for paediatric hypotension.